Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - HEALTHY EXTRACTS INC. | grck-20171004_8kex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): | September 18, 2017 |
GREY CLOAK TECH INC.
(Exact name of registrant as specified in its charter)
Nevada (State or other jurisdiction of incorporation) |
333-202542 (Commission File Number) |
47-2594704 (I.R.S. Employer Identification No.) | ||
10300 W. Charleston Las Vegas, NV 89135 (Address of principal executive offices) (zip code) | ||||
(702) 201-6450 (Registrant’s telephone number, including area code) | ||||
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 – Other Events
Item 8.01 | Other Events |
On September 18, 2017 we executed a Letter of Intent with Eqova Life Sciences, a medically-focused CBD company. The Letter of Intent is non-binding, but the parties expect to consummate the transaction as soon as reasonably practicable.
A press release issued on September 19, 2017 announcing the Letter of Intent is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Section 9 – Financial Statements and Exhibits
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
99.1 | Press release of Premier Biomedical, Inc. dated September 19, 2017. |
- 1 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Grey Cloak Tech Inc. | |
Dated: October 4, 2017 | /s/ William Bossung |
By: William Bossung | |
Its: Chief Financial Officer and Secretary |
- 2 -
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | Press release of Premier Biomedical, Inc. dated September 19, 2017. |